Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026)

Maze Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 132.76% for Q1 2026.

  • On a quarterly basis, EBITDA Margin changed N/A to 132.76% in Q1 2026 year-over-year; TTM through Mar 2026 was 670.26%, a N/A change, with the full-year FY2024 number at 74.77%, changed N/A from a year prior.
  • EBITDA Margin hit 132.76% in Q1 2026 for Maze Therapeutics, down from 49.9% in the prior quarter.
  • Over the last five years, EBITDA Margin for MAZE hit a ceiling of 93.04% in Q2 2024 and a floor of 969.16% in Q3 2024.